Oramed Pharmaceuticals (NASDAQ: ORMP) is predominantly rated as a hold by covering healthcare and biotechnology analysts. Market experts track its clinical-stage pipeline updates and oral drug delivery platform developments closely, maintaining cautious stances due to developmental uncertainties and cash burn risks inherent to small-cap biotechnology equities.